Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2071 to 2085 of 8219 results

  1. Osteoporosis

    In development Reference number: GID-QS10188 Expected publication date: TBC

    Quality standard
    In development

  2. Deutetrabenazine for treating tardive dyskinesia ID6550

    In development Reference number: GID-TA11718 Expected publication date: TBC

    Technology appraisal guidance
    In development

  3. Ruxolitinib for treating moderate atopic dermatitis [ID6602]

    Awaiting development Reference number: GID-TA11809 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  4. Trastuzumab deruxtecan for untreated HER2-mutated unresectable advanced non-small-cell lung cancer [ID6603]

    Awaiting development Reference number: GID-TA11706 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  5. COLOFIT algorithm to guide colorectal cancer pathway referral in primary care: early value assessment

    In development Reference number: GID-HTE10011 Expected publication date: TBC

    Health technology evaluations
    In development

  6. d-NAV for optimization of personal insulin management in adults with type 2 diabetes (MT696)

    Topic prioritisation

    Medical technologies guidance
    Topic prioritisation

  7. Semaglutide for preventing major cardiovascular events in people with cardiovascular disease and overweight or obesity [ID6441]

    In development Reference number: GID-TA11544 Expected publication date:  14 May 2026

    Technology appraisal guidance
    In development

  8. Trastuzumab deruxtecan for adjuvant treatment of high-risk HER2-positive residual invasive breast cancer after neoadjuvant chemotherapy [ID6509]

    In development Reference number: GID-TA11658 Expected publication date: TBC

    Technology appraisal guidance
    In development

  9. Avexitide for treating hypoglycaemia after bariatric surgery [TSID12233]

    Awaiting development Reference number: GID-TA11824 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  10. Mevrometostat with enzalutamide for treating hormone-relapsed metastatic prostate cancer after abiraterone acetate [TSID12239]

    Awaiting development Reference number: GID-TA11827 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  11. Odronextamab for treating relapsed or refractory follicular lymphoma [TSID12236]

    Awaiting development Reference number: GID-TA11829 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  12. Baxdrostat for treating uncontrolled or resistant hypertension [ID6623]

    Awaiting development Reference number: GID-TA11818 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  13. CFHealthHub for managing cystic fibrosis during the COVID-19 pandemic

    Topic prioritisation

    Medical technologies guidance
    Topic prioritisation

  14. Emicizumab for preventing bleeding episodes in people with mild or moderate haemophilia A [ID5098]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  15. Artificial intelligence technologies for mammography: early value assessment

    Awaiting development Reference number: GID-HTE10062 Expected publication date: TBC

    Health technology evaluations
    Awaiting development